UroToday.com shared a post on X:
“RADIOSA Trial: SBRT vs SBRT and ADT for oligorecurrent Prostate Cancer.
Giulia Marvaso shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT and short-course hormonal therapy in oligorecurrent PCa.
Results show enhanced biochemical and clinical progression-free survival with the combination, though select patients may still benefit from SBRT alone. Future analyses will explore QoL and molecular data to refine patient selection.”
Proceed to the video attached to the post.
